Lexston Life Sciences Corp. Announces Listing of its Common Shares on the Canadian Securities Exchange

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

(TheNewswire)



 

Vancouver, British Columbia – TheNewswire - JUNE 23, 2021 - Lexston Life Sciences Corp. (the “Company”) (CNSX:LEXT.CN) is pleased to announce that its common shares will commence trading at market open on June 25, 2021 on the Canadian Securities Exchange under the stock symbol “LEXT”.

 

The Company has a total of 49,968,260 common shares, 2,000,000 options and 18,843,260 warrants issued and outstanding.

 

About Lexston Life Sciences Corp.

Lexston Life Sciences Corp. (“Lexston”) is a Canadian biotechnology company providing cannabis testing and research services.  Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of its services into the psychedelic industry with an initial focus on the detection and quantification of psychedelic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant derived psychedelics in support of burgeoning trials in the field of mental health and wellness.

On Behalf of the Board of Directors


LEXSTON LIFE SCIENCES CORP.

 

Jagdip Bal
Chief Executive Officer
Telephone: (604) 928-8913

    

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

 

Copyright (c) 2021 TheNewswire - All rights reserved.